Mean CCN3 plasma concentration did not differ between groups (MS; 8.58 ± 4.45 ng/ml; HC 10.61 ± 8.29 ng/ml, Fig. 1a), but significantly higher CCN3 levels were observed in patients with progressive MS (PrMS) versus RRMS (PrMS; 12.14 ± 5.86 ng/ml; RRMS 7.89 ± 3.87 ng/ml, Fig. 1b). This evidence concerns the gene CCN3 and myeloid sarcoma.